# A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

> **NCT03588650** · PHASE1 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 26 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** HLX20

## Key facts

- **NCT ID:** NCT03588650
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-07
- **Primary completion:** 2021-06-28
- **Final completion:** 2021-06-28
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2022-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03588650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03588650, "A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03588650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*